Danger Bio

Danger Bio is a preclinical-stage biotechnology company focused on developing first-in-class therapeutics that target the cellular systems responsible for detecting and responding to danger signals, such as infection, injury, and cellular malfunction. Launched in 2021 by Related Sciences with $25.5 million in initial financing, the company leverages a decentralized 'team science' model, collaborating with a global network of over 15 scientific co-founders and 100 drug discovery specialists. Danger Bio's modality-agnostic portfolio includes small molecules, monoclonal antibodies, mRNA, antisense oligonucleotides, and targeted protein degraders. These programs target key innate immunity pathways, including intracellular danger sensors like STING, ADAR1, and cGAS, to address over 60 autoimmune, inflammatory, and oncology indications. The company's drug discovery efforts are powered by Related Sciences' Facets data platform and strategic partnerships with global R&D firms like Evotec.